Evidence map›Paper›PMID 35015145›Full record

ReviewApplied microbiology and biotechnology2022

Probiotics, prebiotics and synbiotics: Safe options for next-generation therapeutics.

Manoj Kumar Yadav, Indu Kumari, Bijender Singh, Krishna Kant Sharma, Santosh Kumar Tiwari

2 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in Applied microbiology and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 207 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
207citing papers in PubMed, 8 pooled it
49.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05885373 nacompletednot on this mapstarted 2023, after this paper: background citation

A Single-arm, Open-label Clinical Study to Evaluate the Effect of SIM01 in Female Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

TypeinterventionalSponsorGenieBiome LimitedRan2023 to 2023Enrolled40ConditionsNon-Alcoholic Fatty Liver DiseaseArmsSIM01
NCT06537882 naactive not recruitingnot on this mapstarted 2024, after this paper: background citation

A Double-blind Randomized Placebo-controlled Study to Evaluate the Effect of Synbiotics SLP07 on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD-RCT)

TypeinterventionalSponsorGenieBiome LimitedRan2024 to 2026Enrolled54ConditionsMetabolic Dysfunction-Associated Fatty Liver DiseaseArmsG-NiiB synbiotics formula (SLP07), Active placebo
3 · Its place in the literature

Who cites it

207 citing papers in PubMed, 8 syntheses or guidelines pooled it, 361 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. AdjuvantMicrobiology spectrum · 2026
    Trial
  10. Trial
  11. Therapeutic Evaluation ofNutrients · 2024
    Trial
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Effects of Araticum (Food science & nutrition · 2026
    Article

147 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Manoj Kumar YadavDepartment of Genetics, Maharshi Dayanand University, Rohtak, 124001, Haryana, India.
Indu KumariDepartment of Genetics, Maharshi Dayanand University, Rohtak, 124001, Haryana, India.
Bijender SinghDepartment of Microbiology, Maharshi Dayanand University, Rohtak, 124001, Haryana, India.
Krishna Kant SharmaDepartment of Microbiology, Maharshi Dayanand University, Rohtak, 124001, Haryana, India.
Santosh Kumar TiwariDepartment of Genetics, Maharshi Dayanand University, Rohtak, 124001, Haryana, India. santoshgenetics@mdurohtak.ac.in.ORCID http://orcid.org/0000-0003-1477-1845
Maharshi Dayanand University · INCentral University of Haryana · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Probiotics have been considered as an economical and safe alternative for the treatment of a large number of chronic diseases and improvement of human health. They are known to modulate the host immunity and protect from several infectious and non-infectious diseases. The colonization, killing of pathogens and induction of host cells are few of the important probiotic attributes which affect several functions of the host. In addition, prebiotics and non-digestible food substances selectively promote the growth of probiotics and human health through nutrient enrichment, and modulation of gut microbiota and immune system. This review highlights the role of probiotics and prebiotics alone and in combination (synbiotics) in the modulation of immune system, treatment of infections, management of inflammatory bowel disease and cancer therapy. KEY POINTS: • Probiotics and their derivatives against several human diseases. • Prebiotics feed probiotics and induce several functions in the host. • Discovery of novel and biosafe products needs attention for human health.

Indexed as

Gastrointestinal MicrobiomeInflammatory Bowel DiseasesProbioticsSynbioticsHumansPrebioticsPrebioticsChronic diseasesHuman healthPrebioticsProbioticsSynbiotics

Identifiers

PMID35015145
PMCPMC8749913
OpenAlexW4206002671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.